Vorinostat and Palliative Radiotherapy

Phase I Study on Suberoylanilide Hydroxyamic Acid (Vorinostat) a Histone Deacetylase Inhibitor, in Palliative Radiotherapy for Advanced Tumors.

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00455351

Acronym

PRAVO

Enrollment

Registered

2007-04-03

Start date

2007-02-28

Completion date

2009-08-31

Last updated

2023-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pelvic Cancer, Radiotherapy

Keywords

Palliative treatment, Max. tolerable dose

Brief summary

Phase I study. Side-effects when combined with standard palliative radiotherapy.

Interventions

DRUGVorinostat

Increasing dosing, phase I

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 100 Years

Healthy volunteers

Inclusion criteria

* Pelvic malignancy * Palliative radiation treatment planed * ECOG \<3 * Age\>18 years

Exclusion criteria

* Previous pelvic radiotherapy * Uncontrolled diarrhea * Insulin-dependent diabetes mellitus * BMI\<18.5

Design outcomes

Primary

Measure	Time frame
DLT	continously

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 31, 2026